Stocks

Dexco (Diabete MedTech company) is delivering on its promises

Dexcom broke $1B in revenue in 2018, plans to outsource some customer support (mobi health news)

  • Continuous glucose monitoring (CGM) giant Dexcom recently reported Q4 2018 earnings, stating it broke USD1bn in annual revenue in 2018 while increasing adoption rates, and announcing outsourcing plans.
  • Q418 revenue of $338m was in line with the Jan. 7th preliminary announcement (“sales to exceed $331m,” BCM est. $288m).
  • Management reiterated sales guidance of 15-20% growth ($1.19-$1.24bn), and set a GM target of 65% with Adj. Op margin of 5.5%, and Adj. EBITDA of 18%.

Analysis and Comments

  • A newly announced restructuring initiative is incremental to forecasts and represents upside to future margin expansion prospects. This should help Dexcom drive leverage as it strives for the 2023 15% operating margin target set at the Dec. 2018 analyst day.
  • This is one of the leading companies in sectors linked to the diabetes value chain that are likely to benefit.

Related posts

Fitbit Is…Another Blue Apron / Snapchat

rollandthomas

Universal Display Corp Ignores The Downgrade

rollandthomas

More $BA Bad News

heyimsnuffles

Get involved!

Comments

No comments yet
s2Member®